.jpg)
Today, the shares of Santhera Pharmaceuticals Holding Ltd, a Swiss specialty pharmaceutical company, were traded in the main market of the SWX Swiss Exchange for the first time. Yesterday, i.e. on Thursday, an issue price of CHF 90 was determined, which is in the middle of the previously specified price range of CHF 85 to CHF 100. The opening price on the SWX was CHF 90.20. This corresponds to a market capitalisation of CHF 265.6 million (excl. greenshoe). Santhera Pharmaceuticals Holding Ltd belongs not only to the SPI®, but also to the SPI EXTRA®.
According to the listing prospectus, of the 2,951,577 registered shares entered in the Commercial Register, 983,859, or 33.3 % of all outstanding shares, were placed with the public. If the option for an additional 147,579 shares is chosen (greenshoe), the free float may reach 36.5%.
Santhera is a Swiss specialty pharmaceutical company focusing on the discovery, development and commercialization of innovative pharmaceuticals for the treatment of severe neuromuscular diseases. The Company addresses the high unmet medical need associated with these diseases where few, if any, effective therapies currently exist.
In June 2006, Santhera had 49 full-time equivalent (FTE) employees. According to the half-yearly report of 30 June 2006 (unaudited), the company generated a turnover of CHF 0.8 million and a net loss of CHF 11.7 million.
